Ocular Therapeutix Past Earnings Performance
Past criteria checks 0/6
Ocular Therapeutix has been growing earnings at an average annual rate of 4.2%, while the Pharmaceuticals industry saw earnings growing at 10.5% annually. Revenues have been growing at an average rate of 47.5% per year.
Key information
4.2%
Earnings growth rate
19.2%
EPS growth rate
| Pharmaceuticals Industry Growth | 7.3% |
| Revenue growth rate | 47.5% |
| Return on equity | -88.6% |
| Net Margin | -138.1% |
| Next Earnings Update | 07 May 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Ocular Therapeutix makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 58 | -81 | 74 | 0 |
| 30 Sep 23 | 58 | -67 | 76 | 0 |
| 30 Jun 23 | 55 | -91 | 77 | 0 |
| 31 Mar 23 | 52 | -89 | 75 | 0 |
| 31 Dec 22 | 51 | -71 | 72 | 0 |
| 30 Sep 22 | 50 | -59 | 70 | 0 |
| 30 Jun 22 | 50 | -33 | 69 | 0 |
| 31 Mar 22 | 49 | -22 | 68 | 0 |
| 31 Dec 21 | 44 | -7 | 67 | 0 |
| 30 Sep 21 | 39 | -88 | 64 | 0 |
| 30 Jun 21 | 32 | -103 | 59 | 0 |
| 31 Mar 21 | 22 | -131 | 53 | 0 |
| 31 Dec 20 | 17 | -156 | 49 | 0 |
| 30 Sep 20 | 12 | -96 | 49 | 0 |
| 30 Jun 20 | 7 | -103 | 49 | 0 |
| 31 Mar 20 | 6 | -91 | 50 | 0 |
| 31 Dec 19 | 4 | -86 | 47 | 0 |
| 30 Sep 19 | 2 | -78 | 41 | 0 |
| 30 Jun 19 | 2 | -74 | 34 | 0 |
| 31 Mar 19 | 2 | -63 | 27 | 0 |
| 31 Dec 18 | 2 | -60 | 24 | 0 |
| 30 Sep 18 | 2 | -56 | 20 | 0 |
| 30 Jun 18 | 2 | -56 | 22 | 0 |
| 31 Mar 18 | 2 | -61 | 27 | 0 |
| 31 Dec 17 | 2 | -63 | 31 | 0 |
| 30 Sep 17 | 2 | -63 | 33 | 0 |
| 30 Jun 17 | 2 | -57 | 29 | 0 |
| 31 Mar 17 | 2 | -50 | 23 | 0 |
| 31 Dec 16 | 2 | -45 | 18 | 0 |
| 30 Sep 16 | 2 | -43 | 16 | 0 |
| 30 Jun 16 | 2 | -44 | 15 | 0 |
| 31 Mar 16 | 2 | -43 | 14 | 0 |
| 31 Dec 15 | 2 | -40 | 13 | 0 |
| 30 Sep 15 | 2 | -37 | 12 | 0 |
| 30 Jun 15 | 2 | -33 | 11 | 0 |
| 31 Mar 15 | 1 | -29 | 10 | 0 |
| 31 Dec 14 | 1 | -29 | 9 | 0 |
| 30 Sep 14 | 0 | -24 | 7 | -8 |
| 30 Jun 14 | 0 | -20 | 5 | -5 |
| 31 Mar 14 | 0 | -17 | 4 | -2 |
Quality Earnings: 0OT is currently unprofitable.
Growing Profit Margin: 0OT is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 0OT is unprofitable, but has reduced losses over the past 5 years at a rate of 4.2% per year.
Accelerating Growth: Unable to compare 0OT's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 0OT is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (2.6%).
Return on Equity
High ROE: 0OT has a negative Return on Equity (-88.59%), as it is currently unprofitable.